NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On March 27, 2017, Nabriva Therapeutics AG (the “Company”) issued a press release announcing its participation at the Needham and Company investor conference on April 5, 2017. Information about accessing a live webcast and a subsequent replay of the Company’s presentation at the conference is included in the press release, which is attached hereto as Exhibit 99.1 and is incorporated by reference into this Form 8-K.
The Company also intends to meet with additional investors and analysts over the course of the next several weeks. A copy of the materials to be used at these meetings, which will also be referenced at the Company’s presentation at its investor conference, is attached hereto as Exhibit 99.2 and is incorporated by reference into this Form 8-K.
The information in this Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
See Exhibit Index attached hereto.